Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mannitol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.58 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorbitol SCHEMBL11021828 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Sorbitol SCHEMBL1063291 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Mannitol SCHEMBL27402277 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Mannitol SCHEMBL10952803 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Sorbitol SCHEMBL9470802 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Mannitol SCHEMBL29085543 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Mannitol SCHEMBL6690019 | 1.00 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Adonitol SCHEMBL20481325 | 0.94 | LMNA (0.53) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| Mannitol SCHEMBL19987822 | 0.89 | LMNA (0.61) | LMNAL3MBTL1TDP1PDE4ACA5A | |
| E968 SCHEMBL994576 | 0.88 | CA5A (0.50) | LMNAL3MBTL1TDP1PDE4ACA5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2205248-A2 | COMBINATION OF NITRODERIVATIZED STEROID AND BRONCHODILATOR FOR TREATING RESPIRATORY DISEASE | Nicox S.A. (FR) | 2010-07-14 | — | — | EP | claimed |
| WO-2009071990-A2 | NO-DONATING CORDICOSTEROID WITH IMPROVED PHARMACOKINETIC, ANTI-INFLAMMATORY AND VASODILATORY PROPERTIES | TOPIGEN PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090087425-A1 | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease | TOPIGEN PHARMACEUTICALS INC. (CA) | 2009-04-02 | — | — | US | claimed |
| US-20090088411-A1 | No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties | TOPIGEN PHARMACEUTICALS INC. (CA) | 2009-04-02 | — | — | US | claimed |
| WO-2009037584-A2 | COMBINATION OF NITRODERIVATIZED STEROID AND BRONCHODILATOR FOR TREATING RESPIRATORY DISEASE | TOPIGEN PHARMACEUTICALS INC. (US) | 2009-03-26 | — | — | WO | claimed |
| EP-0900233-A1 | NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS | G.D. SEARLE & CO. (US) | 1999-03-10 | — | — | EP | claimed |
| US-5837698-A | DERIVATIVES OF BETA-METHASONE, DEXAMETHASONE, BUDESONIDE AND TRIAMCINOLOLE WITH NITRATE | G. D. SEARLE & CO. (US) | 1998-11-17 | — | — | US | claimed |
| WO-1997041144-A1 | NOVEL STEROID NITRITE AND NITRATE ESTER DERIVATIVES USEFUL AS ANTI-INFLAMMATORY DRUGS | G.D. SEARLE & CO. (US) | 1997-11-06 | — | — | WO | claimed |
| US-3993072-A | Microporous drug delivery device | ALZA CORPORATION (US) | 1976-11-23 | — | — | US | claimed |
| US-12042557-B2 | Rapid establishment and/or termination of substantial steady-state drug delivery | I2O THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| CN-107638562-B | Rapid establishment and/or termination of substantial steady-state drug delivery | 精达制药公司 | 2022-12-02 | — | — | CN | disclosed |
| US-20210236413-A1 | RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY-STATE DRUG DELIVERY | I2O THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10869830-B2 | Rapid establishment and/or termination of substantial steady-state drug delivery | INTARCIA THERAPEUTICS, INC. (US) | 2020-12-22 | — | — | US | disclosed |
| EP-3735944-A1 | RAPID ESTABLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STEADY-STATE DRUG DELIVERY | Intarcia Therapeutics, Inc. (US) | 2020-11-11 | — | — | EP | disclosed |
| US-3971367-A | Intrauterine device having means for changing from uterine-retentive shape to nonuterine-retentive shape | ALZA CORPORATION (US) | 1976-07-27 | — | — | US | disclosed |
| US-3967618-A | Drug delivery device | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | disclosed |
| US-3964482-A | Drug delivery device | ALZA CORPORATION (US) | 1976-06-22 | — | — | US | disclosed |
| US-3948254-A | Novel drug delivery device | ALZA CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3948262-A | Novel drug delivery device | ALZA CORPORATION (US) | 1976-04-06 | — | — | US | disclosed |
| US-3944064-A | Self-monitored device for releasing agent at functional rate | ALZA CORPORATION (US) | 1976-03-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088411-A1 | No-donating corticosteroid with improved pharmacokinetic, anti-inflammatory and vasodilatory properties | NOS1, NOS2, NOS3 | LMNA 3321/4885L3MBTL1 4732/4885TDP1 1355/4885 |
| US-20090087425-A1 | Combination of nitroderivatized steroid and bronchodilator for treating respiratory disease | HSD11B1, HSD11B2, CYP11B1 | LMNA 3384/4885L3MBTL1 4208/4885TDP1 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.